Novartis’ iptacopan hits the mark in rare kidney disease C3G

[cafead]

via Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway.

article source